ClinicalTrials.gg
Enrolling by invitationNCT06311773Updated Jul 24, 2026

Pivotal Trial of the Boomerang Catheter for pDVA

An interventional study of Boomerang Catheter in Chronic Limb-Threatening Ischemia, sponsored by Aveera Medical, Inc.. Enrolling by invitation at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Aveera Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
17th of 82
120 · median 38
Started
2024
with 5 others
No phase
38 of 105
8 open now
Primary completion
2027-03
later than 11 of 19 live
Registered
99th of 105
by date

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 17th largest by planned enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2024, is one of 38 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 99th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

03

Conditions studied

  • Chronic Limb-Threatening Ischemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is age ≥ 18 years
  2. Patient has confirmed clinical diagnosis of Rutherford Category (RC) 5 or 6 Chronic Limb-Threatening Ischemia (CLTI) with previous angiogram or hemodynamic evidence (e.g., ABI ≤ 0.39, TP / TcPO2 \< 30 mm Hg) demonstrating severely diminished arterial perfusion of the index limb.
  3. Assessment by the PI and an Independent Review Committee (IRC) determines that patient has no option for conventional distal bypass, surgical or endovascular therapy for limb salvage.
  4. Inflow artery criteria:

    • Imaging confirmation of patent inflow artery (\< 50% stenosis) from Aortic bifurcation to tibial trifurcation.
  5. Target conduit vein criteria:

    • Duplex ultrasound confirms that vein is free from thrombus, contiguous from the intended anastomosis site through the lateral plantar vein, and ≥ 2.0mm lumen-lumen diameter (with tourniquet applied) throughout.
  6. Patient may be scheduled for a planned minor amputation (toe, ray, or trans-metatarsal) within 30 days after index procedure.
  7. Prior stent(s) to inflow arteries (i.e., Iliac, SFA, Popliteal) are allowed.
  8. Patient is willing and able to provide written .
  9. Patient meets institutional criteria for procedure clearance and is able to comply with study requirements per PI judgement.
  10. Diabetic patients have adequate glycemic control per investigator judgement.
  11. Female patients of have a negative pregnancy test within 7 days prior to index procedure (urine)
  12. Patient is enrolled in a wound care network and has an adequate support network to ensure compliance with medication regimen and follow-up study visits.
  13. PI determines that the primary wound is stable (e.g., not rapidly deteriorating or showing signs of healing).

Exclusion criteria

Exclusion Criteria:

  1. \< 12 months.
  2. Patient has a lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle).
  3. Patient is dialysis dependent.
  4. Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in patients not undergoing dialysis.
  5. Prior peripheral arterial bypass procedure on index limb within 30 days.
  6. Previous major amputation of the target limb or absence of adequate viable tissue for below-ankle (e.g., mid-foot) amputation.
  7. Patient is non-ambulatory due to above-ankle amputation of contralateral limb.
  8. The patient is currently participating in another drug or device study that has not completed the primary endpoint and that clinically interferes with the endpoints of this study per PI judgement.
  9. Patient has known or to materials used during the procedure (cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers) or a known contrast sensitivity that cannot be adequately pre-medicated.
  10. Patient cannot be adequately treated with study medications due to known contraindication to aspirin, ADP antagonists such clopidogrel, prasugrel or ticagrelor, or anticoagulants such as heparin or bivalirudin.
  11. Patient has had a stroke within the previous 3 months with residual Rankin score of ≥ 2.
  12. Class IV heart failure which may compromise patient's ability to safely undergo a percutaneous procedure, per PI judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Treated with Boomerang Catheter

    Device: Boomerang Catheter

Interventions

  • DeviceBoomerang Catheter

    The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.

06

What researchers measure

Primary outcomes

  1. Amputation Free Survival (AFS)

    Freedom from above-ankle amputation of the index limb or death (any cause) at 6 months, compared to a literature derived performance goal.

    Time frame: 6-months

Secondary outcomes

  1. Technical success

    Successful deployment of the Boomerang Catheter to the anastomosis site, creation of an anastomosis, and confirmation of fistula flow using angiography or Doppler ultrasound immediately post catheter activation.

    Time frame: During index procedure

  2. Procedural success

    confirmation of retrograde fistula flow in the target tibial vein conduit at index procedure completion.

    Time frame: Immediately post index procedure

  3. Limb salvage

    Freedom from above-ankle amputation of the index limb.

    Time frame: 3 years post index procedure

  4. Primary patency

    Time from fistula creation to the first intervention to maintain or reestablish flow through the fistula or to fistula occlusion.

    Time frame: 1 year post index procedure

  5. Primary assisted patency

    Time from fistula creation to the first occlusion of the fistula.

    Time frame: 1 year post index procedure

  6. Secondary patency

    Time from fistula creation to abandonment (e.g., decision to decline intervention due to occlusion) of the fistula.

    Time frame: 1 year post index procedure

  7. Target wound healing

    Complete or in-process healing of the patient's target wound(s).

    Time frame: 1, 3, 6, 9-months, and 1-year

  8. Complete wound healing

    Complete healing of all the patient's ischemic wound(s) in the index limb.

    Time frame: 1, 3, 6, 9-months, and 1-year

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 15, 2024
StartActual
Apr 16, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2030
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06311773
Lead sponsor
Aveera Medical, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Apr 16, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jul 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion